Stellate Ganglion Blockade with Local Anesthetic for the Improvement of Hot Flashes in Patients with Prostate Cancer on Androgen Deprivation Therapy

Inclusion Criteria

• Men with prostate cancer (with or without metastatic disease) on androgen deprivation therapy (ADT) for at least 2 months
• Must have greater than 28 hot flashes per week
• Body mass index (BMI) less than 32
• Willingness to undergo image guided intervention
• Must have the ability to understand and the willingness to sign a written informed consent prior to registration on study

Exclusion Criteria

• Conditions that preclude SGB or sham intervention (e.g., anatomic abnormalities of the anterior neck or cervical spine; metastatic disease in or near the cervical spine; goiter; cardiac/pulmonary compromise; sleep apnea; acute illness/infection; coagulopathy or history of bleeding disorder; allergic reactions/contraindications to a local anesthetic or contrast dye)
• Current treatment of prostate cancer with radium or chemotherapy at the time of registration, or within =< 14 days prior to the date of SGB intervention
• Use of treatments in the past two months that can affect HF (e.g., testosterone or androgen supplementation) * Note: Selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine uptake inhibitors, and membrane stabilizers will be allowed but must be on stable unchanged dose for at least 8 weeks prior to registration
• Inability to write, speak, or read in English
• Any other illness or condition that the treating investigator feels would interfere with study compliance or would compromise the patient’s safety or study endpoints